Adult Invasive candidiasis including candidemia 200 mg as single loading dose on Day 1, followed by 100 mg daily, thereafter. Continue therapy for at least 14 days after the last +ve culture. Esophageal candidiasis 100 mg as single loading dose on Day 1, followed by 50 mg daily, thereafter. Duration of treatment: Min of 14 days & for at least 7 days following resolution of symptoms. Paed patient ≥1 mth Invasive candidiasis including candidemia 3 mg/kg as loading dose (not to exceed 200 mg) on Day 1, followed by 1.5 mg/kg (not to exceed 100 mg) daily, thereafter. Continue therapy for at least 14 days after the last -ve culture.
Discontinue use if anaphylactic reactions including shock occur. Infusion-related reactions eg, rash, urticaria, flushing, pruritus, dyspnea, bronchospasm & hypotension. Monitor for worsening hepatic function in patients who develop abnormal LFTs during therapy. Not to be given in patients w/ hereditary fructose intolerance. Hepatic dysfunction, hepatitis, or hepatic failure. Pregnancy & lactation. Not recommended in neonates <1 mth. Infants & childn <2 yr.
Sign Out
